Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Subjects ≤65 Years With Previously Untreated Non-Germinal Center DLBCL
Commercial Sponsor
Acerta Pharma BV
Summary
Eligible participants will be randomised into one of two groups and will receive either acalabrutinib or a placebo, in combination with Rituximab, Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) chemotherapy.